← Back to Search

Behavioural Intervention

Cognitive Rehabilitation for Post-COVID Syndrome

N/A

Recruiting

Led By Anna E Boone, PhD, OTR/L

Research Sponsored by University of Missouri-Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Self-reported cognitive symptoms persisting for at least 6 weeks following COVID-19 infection (Cognitive Failures Questionnaire (CFQ) score >43)

Be between 18 and 65 years old

Must not have

Diagnosis of severe neurological or psychiatric condition(s)

Dementia symptoms as indicated by a score of <23 on the Montreal Cognitive Assessment (MoCA)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-intervention (week 0), week 2, week 4, week 6, week 8, and post-intervention (week 12)

Awards & highlights

No Placebo-Only Group

Summary

This trial will assess if a remote therapy called CO-OP can help people with PCS and cognitive impairments with activity performance, cognition, and quality of life.

Who is the study for?

This trial is for individuals who have had COVID-19 and are struggling with cognitive issues at least 6 weeks after infection. Participants should be able to set personal goals, speak English fluently, give informed consent electronically, and have a past diagnosis of COVID-19. People with severe depression, untreated sleep apnea, prior cancer treatment, serious neurological or psychiatric conditions, or signs of dementia are not eligible.

What is being tested?

The study tests if CO-OP (Cognitive Orientation to daily Occupational Performance) delivered remotely can help improve everyday activity performance, cognition and quality of life in people with Post-COVID Syndrome compared to an inactive control group.

What are the potential side effects?

Since the intervention involves cognitive rehabilitation procedures rather than medication or invasive therapy, significant side effects are not anticipated. However, participants may experience fatigue or frustration during cognitive tasks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I've had memory or thinking problems for over 6 weeks after COVID-19.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with a severe neurological or psychiatric condition.

Select...

I have been diagnosed with dementia based on my MoCA score.

Select...

I am experiencing severe depression.

Select...

I have sleep apnea that hasn't been treated.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-intervention (week 0), week 2, week 4, week 6, week 8, and post-intervention (week 12)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-intervention (week 0), week 2, week 4, week 6, week 8, and post-intervention (week 12)

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-intervention (week 0), week 2, week 4, week 6, week 8, and post-intervention (week 12) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability of Intervention Measure (AIM)

Canadian Occupational Performance Measure (COPM)

Feasibility measures

+3 more

Secondary study objectives

CANTAB Delayed Matching to Sample Subtest

CANTAB Paired Associates Learning Subtest

CANTAB Spatial Working Memory Subtest

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Inactive Control GroupExperimental Treatment1 Intervention

Subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.

Group II: Cognitive Orientation to daily Occupational Performance (CO-OP)Experimental Treatment1 Intervention

Each CO-OP session will last 45 minutes and subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CO-OP Procedures

2022

N/A

~50

0 / 5Eligibility criteria met